Melinta Therapeutics to buy Tetraphase for $39m

Melinta Therapeutics has agreed to acquire Tetraphase Pharmaceuticals Inc, a biopharmaceutical company, for $39 million in cash.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this